Pyrazole-3-carboxamide derivative having 5-HT

1. A compound of the following general formula (I) or its pharmaceutically acceptable salt,

wherein,

A is a 3 to 8 membered ring and may contain 0 to 4 heteroatoms selected from O, S, and N;

R 1 is a C 1 -C 6 alkyl group, or a C 1 -C 6 haloalkyl group;

R 2 is a saturated or partially or all unsaturated monocyclic or bicyclic aryl group, which may be substituted by R 4 ;

R 3 is a hydrogen or halogen atom;

R 4 is a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group, OH, OR 1A , halogen, —(CH 2 )aOH, CO 2 H, CONH 2 , CONHR 1A , CONR 1A R 1A , CN, COR 1A , NH 2 , NHR 1A , NR 1A R 1A , NHCOR 1A , SR 1A , SOR 1A , SO 2 R 1A , SO 2 NH 2 , SO 2 NHR 1A , SO 2 NR 1A R 1A , or NHSO 2 R 1A ; when R 4 has two R 1A , they may be same or different, or R 1A may combine with the other R 1A ;

R 5 is a C 1 -C 6 alkyl group, —(CH 2 )aOH, —(CH 2 )aOR 1B , halogen, CONH 2 , CONR 1B R 1B , COR 1B , SO 2 R 1B , —OCH 2 CH 2 NR 1B R 1B or a C 1 -C 6 haloalkyl group; when p is plural;

R 5 may be the same or different, or R 5 may combine with another R 5 ;

R 1A and R 1B are each independently a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group;

a is 0, 1, or 2;

n is 1, or 2; and

p is 0, 1, 2, 3, 4, or 5.

2. The compound or the pharmaceutically acceptable salt thereof, as described in claim 1 , wherein R 2 is the following Ar 1 , Ar 2 , Ar 3 , or Ar 4 ,

wherein,

R 4 is a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group, OH, OR 1A , halogen, —(CH 2 )aOH, CO 2 H, CONH 2 , CONHR 1A , CONR 1A R 1A , CN, COR 1A , NH 2 , NHR 1A , NR 1A R 1A , NHCOR 1A , SR 1A , SOR 1A , SO 2 R 1A , SO 2 NH 2 , SO 2 NHR 1A , SO 2 NR 1A R 1A , or NHSO 2 R 1A ; when q is plural, R 4 may be the same or different; when R 4 has two R 1A , they may be the same or different, or R 1A may combine with the other R 1A ;

q is 0, 1, 2, or 3;

Y is NH, NR 6 , O, or S;

Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 are each independently N, C, CH, or CR 4 (1, 2, or 3 of Z 1 to Z 6 may represent a nitrogen atom); and

R 6 is hydrogen, a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group, a C 1 -C 6 alkoxy C 1 -C 6 alkyl group, a hydroxyl C 1 -C 6 alkyl group, a halo C 1 -C 6 alkoxy C 1 -C 6 alkyl group, a diC 1 -C 6 alkylamino C 1 -C 6 alkyl group, a mono C 1 -C 6 alkylamino C 1 -C 6 alkyl group, an amino C 1 -C 6 alkyl group, a C 3 -C 8 cyclo C 1 -C 6 alkyl group (said C 3 -C 8 cyclo C 1 -C 6 alkyl group may be substituted with 1 or 2 groups each independently selected from hydroxy, C 1 -C 6 alkoxy and C 1 -C 6 acyloxy, and may have S(sulfur), O(oxygen) or NR 1 ), an aminocarbonyl C 1 -C 6 alkyl group, a mono C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl group, a di C 1 -C 6 alkylaminocarbonyl C 1 -C 6 alkyl group, a hydroxycarbonyl C 1 -C 6 alkyl group or a C 1 -C 6 alkylsulfonyl group:

wherein,

R 4 and q are same as described above, and

Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 and Z 8 are each independently N, C, CH, or CR 4 (1, 2, or 3 of Z 1 to Z 8 may represent a nitrogen atom.

3. The compound or the pharmaceutically acceptable salt thereof, as described in claim 2 , wherein Ar 1 , Ar 2 , Ar 3 , or Ar 4 is represented by the following general formula:

wherein,

R 4 and q are same as described in claim 2 ;

R 6 is hydrogen or a C 1 -C 6 alkyl group; and

(R 4 ) q may be a substitutent on one of the two rings or both rings.

4. The compound or the pharmaceutically acceptable salt thereof, as described in claim 2 , wherein ring A is morpholine, piperidine, pyrrolidine, or azetidine which binds at N;

n is 1;

p is 0, 1, or 2; and

q is 0, 1, or 2.

5. The compound or the pharmaceutically acceptable salt thereof, as described in claim 1 , wherein the compound represented by general formula (I) is selected from the group consisting of

1-methyl-N-[2-(morpholin-4-yl)ethyl]-5-(quinolin-3-yl)-1H-pyrazole-3-carboxamide;

1-methyl-5-{5-methyl-1H-pyrrolo[3,2-b]pyridin-2-yl}-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

1-methyl-N-[2-(morpholin-4-yl)ethyl]-5-{1H-pyrrolo[2,3-b]pyridin-2-yl}-1H-pyrazole-3-carboxamide;

1-methyl-N-[2-(morpholin-4-yl)ethyl]-5-{7H-pyrrolo[2,3-d]pyrimidin-6-yl}-1H-pyrazole-3-carboxamide;

1-methyl-N-[2-(morpholin-4-yl)ethyl]-5-[5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]-1H-pyrazole-3-carboxamide;

1-methyl-5-{5-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{5-fluoro-1H-pyrrolo[2,3-b]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{5-cyano-1H-pyrrolo[3,2-b]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{6-fluoro-1H-pyrrolo[3,2-b]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

1-methyl-N-[2-(morpholin-4-yl)ethyl] 5-{5H-pyrrolo[2,3-b]pirazin-6-yl}-1H-pyrazole-3-carboxamide;

5-{5-cyano-1H-pyrrolo[2,3-b]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{5-fluoro1-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

N-[2-(3,3-difluoroazetidin-1-yl)ethyl]-5-(5-fluoro-1H-indol-2-yl)-1-methyl-1H-pyrazole-3-carboxamide;

N-[2-(azetidin-1-yl)ethyl]-5-(5-fluoro-1H-indol-2-yl)-1-methyl-1H-pyrazole-3-carboxamide;

1-methyl-5-(2-methyl-1H-indol-5-yl)-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-(1,2-dimethyl-1H-indol-5-yl)-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-[1-(2-methoxyethyl)-1H-indol-3-yl]-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-(4-acetamido-1H-indol-2-yl)-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{imidazo[1,2-a]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{6-fluoroimidazo[1,2-a]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{7-fluoroimidazo[1,2-a]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

5-{6-cyanoimidazo[1,2-a]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide;

N-[2-(3,3-difluoroazetidin-1-yl)ethyl]-1-methyl-5-(quinolin-3-yl)-1H-pyrazole-3-carboxamide;

N-[2-(3,3-difluoroazetidin-1-yl)ethyl]-1-methyl-5-{1H-pyrrolo[2,3-b]pyridin-2-yl}-1H-pyrazole-3-carboxamide; and

5-{7-cyanoimidazo[1,2-a]pyridin-2-yl}-1-methyl-N-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-3-carboxamide.

6. A compound represented by the following general formula (1A):

wherein, A is a 3 to 8 membered ring and may contain 0 to 4 heteroatoms selected from O, S, and N;

R 1 is a C 1 -C 6 alkyl group, or a C 1 -C 6 haloalkyl group;

R 3 is a hydrogen or halogen atom;

R 5 is a C 1 -C 6 alkyl group, —(CH 2 ) a OH, —(CH 2 )aOR 1 B, halogen, CONH 2 , CONR 1B R 1B , COR 1B , SO 2 R 1B , —OCH 2 CH 2 NR 1B R 1B or a C 1 -C 6 haloalkyl group; when p is plural, R 5 may be the same or different, or R 5 may combine with another R 5 ;

R 1B is a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group;

a is 0, 1, or 2;

n is 1, or 2; and

p is 0, 1, 2, 3, 4, or 5.

7. A therapeutic agent for diseases in which 5-HT 2B receptors are involved, wherein the compound or the pharmaceutically acceptable salt thereof, as described in claim 1 , is an effective ingredient.

8. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof, as described and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition for treatment of a disease condition mediated by 5-HT 2B receptors, in a mammalian subject, comprising an effective amount of the compound or the pharmaceutically acceptable salt thereof, as described and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising the compound as described in claim 1 as a pharmacologically active agent, and further comprising another pharmacologically active agent.

11. The compound or the pharmaceutically acceptable salt thereof, as described in claim 1 , for treatment of a disease condition mediated by 5-HT 2B receptors.

12. A method of treatment for migraine, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, irritable bowel syndrome, asthma, osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, glomerulonephritis, nephritis, dermatitis, hepatitis, vasculitis, renal ischemia, cerebral stroke, myocardial infarction, cerebral ischemia, Alzheimer's disease, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH), idiopathic interstitial pneumonia, bronchitis, liver fibrosis, cryptogenic fibrosing alveolitis, multiple sclerosis, depression, anxiety or obesity, which is characterized by administering an effective amount of a pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof as described in claim 1 and a pharmaceutically acceptable carrier, to human or a mammalian subject.